1. Home
  2. STT vs NTRA Comparison

STT vs NTRA Comparison

Compare STT & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo State Street Corporation

STT

State Street Corporation

HOLD

Current Price

$128.04

Market Cap

32.3B

Sector

Finance

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$227.22

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STT
NTRA
Founded
1792
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.3B
27.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
STT
NTRA
Price
$128.04
$227.22
Analyst Decision
Buy
Strong Buy
Analyst Count
13
16
Target Price
$127.92
$229.56
AVG Volume (30 Days)
1.6M
1.5M
Earning Date
01-16-2026
11-06-2025
Dividend Yield
2.59%
N/A
EPS Growth
49.61
N/A
EPS
9.43
N/A
Revenue
$13,626,000,000.00
$2,116,676,000.00
Revenue This Year
$8.21
$32.77
Revenue Next Year
$4.53
$16.51
P/E Ratio
$13.74
N/A
Revenue Growth
8.59
38.17
52 Week Low
$72.81
$125.38
52 Week High
$130.03
$246.90

Technical Indicators

Market Signals
Indicator
STT
NTRA
Relative Strength Index (RSI) 70.00 54.84
Support Level $122.04 $233.67
Resistance Level $124.21 $246.90
Average True Range (ATR) 2.58 6.69
MACD 1.13 -2.40
Stochastic Oscillator 80.05 9.94

Price Performance

Historical Comparison
STT
NTRA

About STT State Street Corporation

State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $49 trillion in assets under custody and administration, and $5.1 trillion in assets under management, as of June 30, 2025, State Street operates globally in more than 100 geographic markets and employs about 53,000 worldwide.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: